From the quarterly report:
NOX66 works. I expect the share price to increase once the convertible note finance is replaced.
- NOX66 + LuPSMA much better than LuPSMA alone
- Survival data for first 32 patients to be released 13 Feb
- NOX66 + EBRT responses clearly superior to current standard-of-care
- Multi-national, placebo controlled Phase 2b trial being organised
- NOX expects NOX66 to BECOME the standard-of-care
- NOX66 being used for compassionate treatment with either EBRT or LuPSMA
- Could they charge for this?
- New drug being developed to treat brain cancer
- Long-term funding likely to replace convertible notes
- Forums
- ASX - By Stock
- Ann: Noxopharm Dec 2019 Appendix 4C
From the quarterly report: NOX66 + LuPSMA much better than...
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.2¢ |
Change
0.002(2.86%) |
Mkt cap ! $21.04M |
Open | High | Low | Value | Volume |
7.2¢ | 7.2¢ | 7.2¢ | $1.367K | 18.99K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 72463 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 8810 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14000 | 0.068 |
1 | 1672 | 0.066 |
1 | 15000 | 0.065 |
1 | 79000 | 0.063 |
1 | 100000 | 0.062 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 8810 | 1 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
0.080 | 100000 | 1 |
Last trade - 15.33pm 26/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |